ArticleFrontiers in genetics2025
Case Report: Adenylosuccinate lyase deficiency type I caused by splicing disruption due to a novel missense variant in the
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: Insights in human and medical genomics 2024.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenylosuccinate lyase deficiency (ALD) is a rare neurometabolic disorder caused by biallelic loss-of-function variants in the ADSL gene. We report a severe type I ALD case involving a 2-year-old boy presenting with early-onset polymorphic seizures (clonic/myoclonic), developmental delay, and progressive neurological deterioration. Seizures were temporarily controlled with ethosuximide and vigabatrin, though neurodegeneration progressed. Analysis of whole-exome sequencing data revealed compound-heterozygous variants in the ADSL gene: the known pathogenic missense variant c.340T>C (p.Tyr114His) and a novel variant c.859A>G (p.Ile287Val). Although p.Ile287Val is predicted to be benign at the protein level, RNA analysis demonstrated that c.859A>G activates a cryptic splice site in exon 8, resulting in aberrant transcripts (64%, 4-bp deletion, targeted by nonsense-mediated decay) and a smaller proportion of normal transcripts (36%) encoding the p.Ile287Val protein. This case highlights splicing disruption as a novel pathogenic mechanism in ALD and expands the mutational spectrum associated with the disease. This case also underscores the importance of integrating RNA analysis with genomic data to uncover cryptic splicing defects, especially when protein-level predictions suggest benignity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.